Physician profile
Ellen Labauve
NPI 1821613936
$1,038.26
in general payments reported to CMS, 2019-2025
15 companies · $625 in 2025
The $625 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.47 · 2022: $173 · 2023: $19.91 · 2024: $198 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $843.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $207.69 | 2025 | Myosure Tissue Removal Device, Fluent Fluid Management System, Novasure |
| Ethicon US, LLC | $151.97 | 2022-2024 | Stratafix, Dermabond |
| Organon LLC | $145.50 | 2024-2025 | Nexplanon |
| Shield Therapeutics INC | $93.09 | 2024 | |
| Mayne Pharma Commercial LLC | $89.12 | 2025 | |
| Sage Therapeutics, LLC | $63.14 | 2024-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $56.52 | 2024-2025 | |
| Davol INC. | $43.08 | 2022 | |
| Sumitomo Pharma America, INC. | $42.17 | 2023-2025 | Myfembree |
| Coopersurgical, INC. | $34.03 | 2025 | Ally II Ups |
| Exeltis, USA INC. | $32.97 | 2025 | Slynd |
| Pfizer INC. | $27.84 | 2025 | |
| Boston Scientific Corporation | $21.47 | 2021 | |
| Supernus Pharmaceuticals, INC. | $15.34 | 2025 | Qelbree |
| Astellas Pharma US INC | $14.33 | 2024 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Labauve listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.